Literature DB >> 2157505

Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson's dementia.

J M Rabey1, M Scharf, Z Oberman, M Zohar, E Graff.   

Abstract

The dexamethasone suppression test (DST) has been suggested as an effective tool for differentiating between depression and dementia. After administering 1 mg dexamethasone, we measured cortisol, ACTH, and beta-endorphin levels in 32 nondepressed patients with idiopathic Parkinson's disease (PD) (14 also with dementia) and 20 healthy, age-matched controls. Four of the 20 controls, 9 of the 18 with PD alone, and 8 of the 14 with PD and dementia were dexamethasone nonsuppressors (cortisol value greater than or equal to 5 micrograms/100 ml). PD patients without dementia (nonsuppressors) showed higher basal plasma values of cortisol (22.06 +/- 5.30 micrograms/100 ml) compared with the suppressors (13.38 +/- 3.30 micrograms/100 ml). Plasma ACTH and beta-endorphin responded in a coupled way to dexamethasone challenge. Higher basal levels of both peptides were found among PD patients (demented and nondemented), nonresponders to DST. Thus, the DST does not appear to be effective in differentiating between depression and dementia in PD. In addition, PD nonsuppressors showed higher basal values of plasma ACTH, beta-endorphin, and cortisol (similar to patients with major depression). This suggests that although the depression is clinically undetectable, both disorders may share some pathophysiological features at the hypothalamic hypophyseal adrenal level.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157505     DOI: 10.1016/0006-3223(90)90525-7

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  5 in total

Review 1.  Depression in Parkinson's disease. Pharmacological characteristics and treatment.

Authors:  T Tom; J L Cummings
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

2.  Diurnal salivary cortisol concentrations in Parkinson's disease: increased total secretion and morning cortisol concentrations.

Authors:  O Skogar; P-A Fall; G Hallgren; J Lökk; B Bringer; M Carlsson; U Lennartsson; H Sandbjork; C-J Törnhage
Journal:  Int J Gen Med       Date:  2011-08-10

Review 3.  Is Dysregulation of the HPA-Axis a Core Pathophysiology Mediating Co-Morbid Depression in Neurodegenerative Diseases?

Authors:  Xin Du; Terence Y Pang
Journal:  Front Psychiatry       Date:  2015-03-09       Impact factor: 4.157

Review 4.  Chronic Stress and Glucocorticoids: From Neuronal Plasticity to Neurodegeneration.

Authors:  Sheela Vyas; Ana João Rodrigues; Joana Margarida Silva; Francois Tronche; Osborne F X Almeida; Nuno Sousa; Ioannis Sotiropoulos
Journal:  Neural Plast       Date:  2016-03-10       Impact factor: 3.599

5.  TLR9 activation via microglial glucocorticoid receptors contributes to degeneration of midbrain dopamine neurons.

Authors:  Layal Maatouk; Anne-Claire Compagnion; Maria-Angeles Carrillo-de Sauvage; Alexis-Pierre Bemelmans; Sabrina Leclere-Turbant; Vincent Cirotteau; Mira Tohme; Allen Beke; Michaël Trichet; Virginie Bazin; Bobby N Trawick; Richard M Ransohoff; François Tronche; Bénédicte Manoury; Sheela Vyas
Journal:  Nat Commun       Date:  2018-06-22       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.